Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
Market Cap & Net Worth: Argen-X (0QW0)
Argen-X (LSE:0QW0) has a market capitalization of $20.46 Billion (€19.93 Billion) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #1328 globally and #60 in its home market, demonstrating a -0.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Argen-X's stock price €614.30 by its total outstanding shares 32450800 (32.45 Million).
Argen-X Market Cap History: 2015 to 2026
Argen-X's market capitalization history from 2015 to 2026. Data shows growth from $309.78 Million to $20.46 Billion (50.20% CAGR).
Argen-X Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Argen-X's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.17x
Argen-X's market cap is 9.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
24.79x
Argen-X's market cap is 24.79 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $309.78 Million | $7.49 Million | -$16.74 Million | 41.34x | N/A |
| 2016 | $443.02 Million | $15.47 Million | -$22.48 Million | 28.63x | N/A |
| 2017 | $1.63 Billion | $43.69 Million | -$33.68 Million | 37.38x | N/A |
| 2018 | $2.83 Billion | $24.57 Million | -$76.23 Million | 115.36x | N/A |
| 2019 | $4.80 Billion | $78.46 Million | -$181.21 Million | 61.18x | N/A |
| 2020 | $8.04 Billion | $41.24 Million | -$608.46 Million | 194.97x | N/A |
| 2021 | $10.50 Billion | $497.28 Million | -$408.26 Million | 21.12x | N/A |
| 2022 | $11.70 Billion | $410.75 Million | -$709.59 Million | 28.48x | N/A |
| 2023 | $11.50 Billion | $1.23 Billion | -$295.05 Million | 9.38x | N/A |
| 2024 | $19.94 Billion | $2.17 Billion | $804.13 Million | 9.17x | 24.79x |
Competitor Companies of 0QW0 by Market Capitalization
Companies near Argen-X in the global market cap rankings as of March 18, 2026.
Key companies related to Argen-X by market ranking:
- Intra-Cellular Therapies Inc (NASDAQ:ITCI): Ranked #1319 globally with a market cap of $13.82 Billion USD.
- Repsol SA (OTCQX:REPYY): Ranked #1320 globally with a market cap of $13.82 Billion USD.
- Jones Lang LaSalle Incorporated (NYSE:JLL): Ranked #1329 globally with a market cap of $13.70 Billion USD.
- Yankuang Energy Group Co Ltd (SHG:600188): Ranked #1330 globally with a market cap of $13.64 Billion USD ( CN¥100.09 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1319 | Intra-Cellular Therapies Inc | NASDAQ:ITCI | $13.82 Billion | $131.87 |
| #1320 | Repsol SA | OTCQX:REPYY | $13.82 Billion | $11.81 |
| #1329 | Jones Lang LaSalle Incorporated | NYSE:JLL | $13.70 Billion | $303.00 |
| #1330 | Yankuang Energy Group Co Ltd | SHG:600188 | $13.64 Billion | CN¥21.77 |
Argen-X Historical Marketcap From 2015 to 2026
Between 2015 and today, Argen-X's market cap moved from $309.78 Million to $ 20.46 Billion, with a yearly change of 50.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.46 Billion | -14.12% |
| 2025 | €23.83 Billion | +19.52% |
| 2024 | €19.94 Billion | +73.30% |
| 2023 | €11.50 Billion | -1.65% |
| 2022 | €11.70 Billion | +11.37% |
| 2021 | €10.50 Billion | +30.62% |
| 2020 | €8.04 Billion | +67.52% |
| 2019 | €4.80 Billion | +69.33% |
| 2018 | €2.83 Billion | +73.60% |
| 2017 | €1.63 Billion | +268.57% |
| 2016 | €443.02 Million | +43.01% |
| 2015 | €309.78 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Argen-X was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.46 Billion USD |
| MoneyControl | $20.46 Billion USD |
| MarketWatch | $20.46 Billion USD |
| marketcap.company | $20.46 Billion USD |
| Reuters | $20.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.